Aidoc, the medical AI company with the most FDA certificates, completed a $110 million Series D financing news, as the medical AI company with the most FDA-approved products, Aidoc recently announced the completion of a $110 million Series D investment. This round of investment was jointly led by TCV and Alpha Intelligence Capital (AIC), with participation from CDIB Capital.

This round of financing will be used to expand Aidoc’s AI-powered care platform to the more than 1,000 hospitals and health centers it is serving.


In 2016, Aidoc was co-founded by its CEO Elad Walach, CTO Michael Braginsky, and VP R&D and CISO Guy Reiner.

The company’s AI medical platform, the first in its field, collaborates with doctors and manages a patient’s entire treatment cycle: from diagnostic assistance, consultation, and suggested treatment options to follow-up medical aids and patient follow-up. To date, the company has 15 FDA-approved clinical medical solutions.

With Aidoc’s performance in the field of medical AI, the company was previously named one of the 50 genius companies by Time magazine, and its founder was also listed on the Forbes Under 30 list.


In clinical use, its solutions serve departments such as hospital radiology departments in a “SaaS + cloud” manner, and customers only need to purchase a license and pay an annual fee to obtain the right to use the software.

Hospitals don’t need dedicated hardware, just receive scans through the Picture Archiving, Communications and Radiology Information System (PACS), where radiologists and other imaging specialists can classify cases, and the Aidoc system automatically identifies and flags abnormalities , so as to prioritize critical cases and speed up treatment.

Currently in clinical studies, Aidoc AI has been shown to reduce patient transfers, shorten hospital stays, and increase recovery rates, and is currently used in most leading local hospitals in Israel.

Aidoc currently has 250 employees in Israel and 100 in the rest of the world, according to Walach. Compared to 70 employees at the end of 2020, the company’s headcount has grown fivefold. This also shows that in the new crown epidemic, due to factors such as shortage of doctors and nurses, rising supply costs, and changing economic and political environments, AI medical care platforms have become more popular.

But today, healthcare systems around the world still face enormous challenges.

According to data analytics firm Morning Consult, hospitals across the U.S. are currently facing a growing labor shortage. Among them, 30% of doctors chose to retire, and 31% of doctors had considered leaving the health care industry, resulting in delays in medical service care, difficulties in handover, and even lack of nursing care.

These health care problems have now added to hospital operating costs, and as of April 2022, operating profit margins for U.S. hospitals have been in the red for four consecutive months. Within five years, the U.S. healthcare workforce shortage is projected to reach 3.2 million people.

The Global Health Workforce Strategy 2030 issued by the World Health Organization estimates that by 2030, there will be a shortage of 18 million medical workers worldwide. The impact of an ongoing shortage of healthcare workers will be most severe in low- and middle-income countries, as healthcare workers will migrate first to richer countries.

Under the dual crisis of medical care shortage and operating cost, Aidoc’s medical AI platform will take the lead in addressing these outstanding problems.

In June, Aidoc announced an agreement with Spain’s largest academic medical center, Hospital Clinic Barcelona (HCB), to deploy its AI platform on three solutions for intracranial hemorrhage (ICH), pulmonary embolism (PE) and incidental pulmonary embolism (iPE). middle.

In May, French medical technology company Gleamer announced a partnership with Aidoc to integrate Gleamer’s X-ray BoneView software into the Aidoc platform. The integrated Aidoc platform will be used to help identify and localize fractures in the limbs, pelvis, thoracic and lumbar spine, and ribs in X-ray images, solidifying Aidoc’s entry into the X-ray field.

Earlier, Aidoc announced an agreement with Atlantic Health System in New Jersey, which will allow Atlantic Health physicians to use Aidoc’s platform to triage patients’ CT scans for emergencies such as potential cerebral hemorrhage, cervical fractures, Conditions such as blood clots in the lungs, broken ribs and intestinal damage.

Commenting on the financing, TCV partner Gopi Vaddi said: “Aidoc has built a bold vision to create a new market category in healthcare with a patient-centric and product-centric philosophy, and in the field of medical imaging. Rooted. We believe Aidoc’s platform will transform the way hospitals operate and become the smart tool needed to transform healthcare.”

Uday Sandhu, Partner at Alpha, said: “With this new funding round, we are excited to strengthen our existing partnership with the Aidoc team, whose products are making a real impact on patient care at some of the world’s leading healthcare institutions.”

“AIC invests in companies with decisive algorithmic advantages, and we believe Aidoc has a unique opportunity to continue leveraging its AI expertise to improve patient outcomes and make physicians and hospitals more efficient,” said the AIC investor.


Leifeng Network

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.